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Abstract
The identification of disease markers in
human body fluids requires an extensive and
thorough analysis of its protein constituents. In
the present study, we have extended our analy-
sis of the human cerebrospinal fluid (CSF) pro-
teome using protein prefractionation followed
by shotgun mass spectrometry. After the re-
moval of abundant protein components from
the mixture with the help of immunodepletion
affinity chromatography, we used either anion
exchange chromatography or sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) to further subfractionate the proteins
present in CSFs. Each protein subfraction was
enzyme digested and analyzed by tandem mass
spectrometry and the resulting data evaluated
using the Spectrum Mill software. Different 
subfractionation methods resulted in the identifi-
cation of a grant total of 259 proteins in CSF
from a patient with normal pressure hydro-
cephalus. The greatest number of proteins, 240
in total, were identified after prefractionating
the CSF proteins by immunodepletion and SDS-
PAGE. Immuno-depletion combined with anion
exchange fractionation resulted in 112 proteins
and 74 proteins were found when only immun-
odepletion of the CSF sample was carried out.
All methods used showed a significant increase
in the number of identified proteins as com-
pared with nondepleted and unfractionated CSF
sample analysis, which yielded only 38 protein
identifications. The present work establishes a
platform for future studies aimed at a detailed
comparative proteome analysis of CSFs from
different groups of patients suffering from vari-
ous psychiatric and neurological disorders.
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Introduction
A study by the World Health Organization
has found that diseases of the central nervous
system are affecting a significant portion of
the population and are among the leading
causes of death in Western societies (1).
Although great advances have been made in
our understanding of the pathophysiology of
psychiatric and neurological diseases, signifi-
cant gaps remain in our knowledge about
their ultimate causes.
Because it constantly perfuses brain tissue,
cerebrospinal fluid (CSF) represents a lavage
of sorts and hence contains mediators that
reflect metabolic processes in the brain. In this
regard, it is likely that CSF contains proteins
that are secreted or shed from brain cells and
can therefore be used for diagnostic purposes
to analyze and quantify proteins and peptides
derived from the brain. Furthermore, CSF can
be obtained in a controlled fashion, minimiz-
ing the dangers of variability introduced at the
sample collection step. For these reasons, CSF
has been used for the analysis of specific pro-
teins in screening several psychiatric and neu-
rological disorders by various immunoassays
(2). It is hypothesized that the changes in CSF
proteins reflect the pathological alterations in
the function of the central nervous system.
Therefore, the comparative analysis of the pro-
teomes of human CSF from diseased and
healthy subjects is becoming increasingly
important for the identification of disease-
specific proteins. It is hoped that these studies
will ultimately result in the discovery of novel
markers of disease and suggest mechanisms
and treatments for psychiatric and neurologi-
cal disorders. For this purpose, CSF samples
from healthy subjects and patients with psy-
chiatric and neurological diseases can be com-
pared using various proteomic methods. In
addition, CSF samples from patients before
and after treatment with specific drugs may 
be able to reveal important differences in an
individual’s response to a certain drug treat-
ment and lead to personalized medicine
approaches. Hence, it is hoped that protein
profiling of CSF will ultimately result in a
better understanding of disease mechanisms
and the molecular effects of drugs.
The analysis of entire proteomes from a
clinical specimen is by no means straightfor-
ward (3). The major hurdle when it comes to
patient samples is the limiting amount of
starting material that is available to carry out
the analysis. Clinical samples, such as body
fluids, frequently cannot be obtained in large
enough amounts. The other reason that the
analysis of the proteome in CSF is difficult is
because of the large dynamic range of protein
concentrations in such fluids, which can be up
to 12 orders of magnitude between the highest
and lowest expressed proteins (3). This range
of protein concentrations exceeds the current
capabilities of proteomic analysis and is a
major barrier in the identification of low abun-
dant proteins in body fluids. Further compli-
cating the analysis of CSF is the possible
infiltration of serum proteins that is caused by
a leaky blood–brain barrier that is especially
pronounced in patients with brain disorders.
As a consequence, it is often impossible to
know if a protein that is found in CSF is
derived from the brain or serum.
Proteome analysis in general involves two
stages: protein separation followed by identi-
fication and analysis. Multidimensional sepa-
rations are required in order to result in an
adequate resolution of complex protein mix-
tures in body fluids. Classical proteomic
approaches use fractionation on the protein
level with the help of two-dimensional-
polyacrylamide gel electrophoresis (2D-PAGE)
(4,5). This technique produces high-resolution
protein separations resulting in the display of
potentially thousands of protein spots. Alter-
natively, tryptic peptides derived from the
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proteins in the mixture can be subjected to
shotgun mass spectrometry analysis. In the
shotgun mass spectrometry approach, proteins
are digested by specific enzymes into small
peptides and analyzed on-line by mass spec-
trometry (6). A major advantage of the shot-
gun mass spectrometry approach is that low
abundant proteins can be identified in the
presence of high abundant proteins, a scenario
that is often encountered when analyzing pro-
tein mixtures from body fluids like serum or
CSF (3).
In a previous study, we have described our
attempts to identify a large number of the con-
stituents of the human CSF proteome (7) using
the shotgun mass spectrometry methodology
(8). This was achieved by depletion of the
most abundant proteins from the mixture with
the help of an immunoaffinity column and
subsequent multidimensional fractionation of
the peptides resulting from an Endoproteinase
Lys-C, trypsin double digest of the remain-
ing proteins and shotgun mass spectrometry
analysis. In the present study, we have ex-
tended the human CSF proteome analysis by
using prefractionation of the immunodepleted
sample on the protein level. Using anion
exchange chromatography (AEC) or sodium
dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE) for protein separation,
we have been able greatly increase the number
of CSF proteins identified. The described in-
depth CSF proteome analysis will greatly
assist our efforts to identify biomarkers for
psychiatric and neurological disorders.
Materials and Methods
Collection of Human CSF
With the subject in the sitting position,
lumbar puncture was performed at the fourth
lumbar intervertebral space using an atrau-
matic needle without local anesthesia. For this
study, CSF from a patient with normal pres-
sure hydrocephalus was used. In order to
remove cellular debris, we centrifuged the
CSF sample and then aliquoted and trans-
ferred it to a 80°C freezer. The CSF sample
used for the studies had the following protein
concentrations: total protein 266 g/mL,
human serum albumin (HSA) 158 g/mL,
immunoglobulin (Ig)G 22.2 g/mL.
Immunodepletion
A total of 6 mL CSF from a patient with
normal pressure hydrocephalus was thawed
on ice and concentrated to 100 µL on a
Vivaspin 5-kDa cartridge (Vivascience AG,
Hannover, Germany) by centrifugation at
2380g at 4°C. This cartridge retains proteins
with a molecular mass >5 kDa; at the same
time, it removes salts and other low-molecular-
weight compounds.
The Vivaspin retentate was washed with
1 mL of buffer A (phosphate salt solution, 
pH 7.4, containing 0.02% NaN3; Agilent
Technologies, Wilmington, DE). This step
was repeated three times and the sample
concentrated to a final volume of 100 µL.
Fifty-microliter aliquots of the concentrated
CSF sample were then loaded onto the Mul-
tiple Affinity Removal System immuno
affinity column, 0.46  50 mm (Agilent Tech-
nologies). The Multiple Affinity Removal
System column removed the following 
proteins from the CSF mixture: HSA, trans-
ferrin, haptoglobin, IgG, IgA, and antitrypsin.
During the immunoaffinity high-pressure
liquid chromatography (HPLC) run, the col-
umn effluents were monitored at 280 nm 
with a flow rate of 250 µL/min for sample
loading and collection of the flow-through
fraction. For column elution, the flow was
increased to 1 mL/min. Typically, the flow-
through fraction containing the depleted
CSF protein mixture eluted in a volume of 
1.5–2 mL. Elution of the absorbed proteins was
carried out with a urea buffer at pH 2.5 (Buf-
fer B; Agilent Technologies) at a flow rate of 
1 mL/min.
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Sample Preparation for Direct Shotgun
Mass Spectrometry
The immunoaffinity column flow-through
fraction was concentrated on a Vivaspin 5-kDa
cartridge (Vivascience AG) as described above,
washed three times with 1 mL 200 mM
NH4HCO3 at pH 8.5 and concentrated to a
final volume of 50 L. For digestion, the
sample was adjusted to 8M urea and proteins
reduced with 10 mM dithiothreitol (DTT) at
37°C in the dark for 1 h and alkylated with
50 mM iodoacetamide at 37°C in the dark for
30 min. The sample was then diluted to 2 M
urea with 200 mM NH4HCO3 at pH 8.5 and
digested with 10 µg Endoproteinase Lys-C
(Roche Diagnostics, Indianapolis, IN) at 37°C
overnight. The next day, 10 µg of trypsin
(Promega, Madison, WI) was added and the
incubation continued at 37°C overnight. The
treatment with two enzymes leads to a more
efficient digestion of the substrate proteins. In
addition, peptide bonds after lysine residues
that are preceded by a proline residue are not
cleaved by trypsin but are amenable to cleav-
age with Endoproteinase Lys-C.
After digestion, salts were removed by
using a SPEC Plus PT pipette tip solid phase
extraction cartridge (Varian Inc., Palo Alto,
CA) according to the manufacturer’s instruc-
tions. Peptides were eluted from the SPEC car-
tridge with two aliquots of 20 µL 95%
acetonitrile, 0.1% formic acid. Finally, the ace-
tonitrile was removed by vacuum centrifu-
gation and the remaining mixture dissolved 
in 40 µL 5 mM KH2PO4, 25% acetonitrile at 
pH 3.0.
Anion Exchange Chromatography
The depleted CSF sample was washed three
times with 20 mM Tris-HCl at pH 8.0, using
a Vivaspin 5-kDa cartridge (Vivascience AG)
as described above and concentrated to 100 
µL. The sample was then manually loaded 
onto a strong anion exchange macro trap
cartridge, 3  8 mm (Michrom BioSources, Inc.,
Auburn, CA). Proteins were eluted with 100
µL 20 mM Tris-HCl, pH 8.0, buffer containing
20 mM, 50 mM, 100 mM, 150 mM, 200 mM,
300 mM, 400 mM, and 500 mM of NaCl. The
eluted fractions were collected and concen-
trated and washed three times with 200 mM
NH4HCO3 at pH 8.5 to a final volume of 50 µL
with a Vivaspin 5-kDa cartridge (Vivascience
AG) as described above. The protein mixtures
from the eight salt fractions were adjusted to
8 M urea and reduced and alkylated as des-
cribed above. The samples were then diluted
to 2 M urea with 200 mM NH4HCO3 at pH 8.5
and digested and processed as described
above.
SDS-Polyacrylamide Gel Electrophoresis
The depleted CSF was washed three times
with 200 mM NH4HCO3 at pH 8.5, concen-
trated to 50 µL with a Vivaspin 5-kDa (Viva-
science AG) cartridge, and reduced and
alkylated as described above. The dried
sample was dissolved in 30 µL of SDS sample
buffer (125 mM Tris-HCl, pH 8.0, 9.2% SDS,
0.39 M DTT, 40% glycerol, 0.001% bromophe-
nol blue) and loaded onto a 12% SDS poly-
acrylamide gel using a Protean Plus Cell
apparatus (Bio-Rad Laboratories, Hercules,
CA). After electrophoresis, the proteins were
stained with colloidal Coomassie Blue and
scanned with a densitometer (Bio-Rad Lab-
oratories). The protein-containing gel lane was
cut in 5  1 mm slices, which were destained
two times with 70 µL acetonitrile/20 mM
NH4HCO3 at pH 8.5 (1:1) at 37°C for 30 min
and then dried under a fume hood. For diges-
tion, 1 µg trypsin in 30 µL 20 mM NH4HCO3
at pH 8.5 was added to each gel slice. The
enzymatic reaction was carried out at 37°C
overnight. After the digestion, the peptides
were extracted by adding 5% formic acid at
37°C for 30 min. The gel pieces were spun
down and the liquid collected. The extraction
was repeated twice. Finally, the extracted
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digest peptide mixture was lyophilized to
dryness and dissolved in 12 µL 0.1% formic
acid.
Mass Spectrometry Analysis
Strong Cation Exchange Chromatography
After digestion and desalting, the CSF
digest peptide mixture was loaded onto an
SCX cation exchange column, 0.5  15 mm
(Dionex, Sunnyvale, CA) that had been equili-
brated in 5 mM KH2PO4, 25% acetonitrile at
pH 3.0 at a flow rate of 30 µL/min. After
washing the column with buffer A for 5 min,
peptides were eluted by applying a linear gra-
dient from 0 to 50% of 25% acetonitrile, 350
mM KCl at pH 3.0. Fractions were collected at
1-min intervals and lyophilized to dryness.
The peptides were then dissolved in 36 µL
0.1% formic acid.
Liquid Chromatography/Tandem Mass 
Spectrometry (LC/MS/MS) Analysis
One-third of each cation exchange fraction
(12 µL) was loaded onto a PicoFrit RP-C18
column, 0.075  10 mm (New Objective Inc.,
Woburn, MA) in 0.1% formic acid (solvent A1),
washed with solvent A1 for 15 min, and eluted
with a linear gradient of 95% acetonitrile/0.1%
formic acid (solvent B1) over 90 min at a flow
rate of 200 nL/min using the ULTIMATE
nano-HPLC system (Dionex). Column effluents
were directly infused into an LCQ DECA XP
PLUS iontrap mass spectrometer (Thermo
Electron Corp., San Jose, CA). For mass spec-
trometry analysis, three separate runs were
carried out for each cation exchange fraction.
In each run, the four most abundant precur-
sor ions were subjected to fragmentation and
MS/MS analysis. Different mass/charge (m/z)
limits were used for the full scan in each run
(400–900, 900–1500, 1500–2000). The mass spec-
trometer was operated with an ion spray volt-
age of 1.1 kV, a normalized collision energy of
35%, a default charge state of +3, an isolation
width of 4 amu, a reject mass width of 0.5, a
dynamic exclusion of 3 min, an exclusion mass
width of 3 amu, a repeat count of 2, and a
repeat duration of 0.35 min.
Data Analysis
All MS/MS spectra were processed and
analyzed using the Spectrum Mill software
and default parameters (Agilent Technologies,
Santa Clara, CA) (9). After the extraction step
during which MS/MS spectra of low quality
were removed, the spectra were searched
against the human international protein 
index (IPI) database, version 2.29, 03/05/2004
(EBI, Cambridgeshire, UK) with the static
chemical modification of +57 Dalton (Cys-
carboxyamidomethyl) and a precursor ion
accuracy of 3 Dalton. For a protein identifica-
tion to be autovalidated in Spectrum Mill, the
protein needs to have a score (sum of peptide
scores that map to that protein) of >20. For
a “one-hit wonder” to pass Spectrum Mill’s
autovalidation routine, in peptide validation
mode, the peptide must have a score of 13 or
greater. In addition, using the same parame-
ters, all MS/MS spectra were also searched
against a reversed human IPI database in order
to assess the frequency of false-positive hits.
Results and Discussion
A major hurdle of the proteome analysis of
body fluids such as CSF is the rather large
dynamic range of the proteins present in the
mixture. It is estimated that in CSF and serum
the range of protein concentrations spans 12
orders of magnitude (3). As a consequence, the
identification of proteins lower in concentra-
tion than the very abundant HSA and Ig is
extremely difficult. To circumvent the problem
caused by the large dynamic range of protein
expression, several approaches have been
developed that will deplete the most abundant
proteins from body fluids. In our previous
studies, we have shown that an immunoaffinity
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matrix that is made up of affinity-purified
polyclonal antibodies against the six major
proteins in serum (HSA, transferrin, hap-
toglobin, IgG, IgA, and antitrypsin) also re-
moves the six most abundant proteins from
CSF and thereby allows the identification by
mass spectrometry of a great number of low
abundant proteins in CSF (7). Because of its
great specificity, we have been using the Mul-
tiple Affinity Removal System for all our sub-
sequent studies that are geared toward an
in-depth proteome analysis of human CSF.
CSF from a patient with normal pressure
hydrocephalus was used for all our studies
because of the relatively large volume of fluid
that can be obtained. This is critical because it
allows one to perform several experiments
with the same CSF sample whose results
can be compared for proteomic method
development.
In our previous CSF proteomic studies, we
used immunodepletion followed by shotgun
mass spectrometry analysis of the peptide (7).
In order to extend our proteome mining
efforts and increase the number of identified
proteins, we reasoned that further fractiona-
tion on the intact protein level of the CSF
sample mixture is necessary. For this purpose,
we used either AEC or SDS-PAGE (Fig. 1). In
the case of AEC, absorbed proteins from the
immunodepleted CSF sample were eluted in
a stepwise fashion with increasing concentra-
tions of salt. An aliquot of each fraction was
analyzed by SDS-PAGE in order to gauge the
success of the separation (Fig. 2A). The pro-
teins from each salt fraction were digested and
the resultant peptide mixtures subjected to
two rounds of chromatography (strong cation
exchange and reversed phase) and on-line
tandem mass spectrometry (7).
In the other prefractionation experiment, we
loaded the immunodepleted and concentrated
CSF protein mixture onto an SDS polyacryl-
amide gel. After electrophoresis and gel stain-
ing (Fig. 2B), the lane containing the CSF
sample was cut into 1-mm slices. Each of 
a total of 146 slices was then subjected to 
an in-gel digest followed by shotgun mass
spectrometry.
For all analyses, the nano reversed phase
column-eluting peptides were processed on-
line by tandem mass spectrometry of the four
strongest signals from each full scan. The
MS/MS spectra acquired by the mass spec-
trometer were analyzed for matching peptide
sequences against the human IPI protein
database and a reversed sequence version of
the same database using the Spectrum Mill
software (9). In the case of single peptide hits,
the MS/MS spectra were further inspected
manually to confirm the obtained sequence.
Processing the CSF sample by only immuno-
depletion and no further protein prefractiona-
tion followed by shotgun mass spectrometry
resulted in 74 proteins identified. Protein sep-
aration of the immunodepleted CSF sample
with the help of AEC with eight salt fractions
collected yielded 112 protein hits. Prefraction-
ation of the same sample by SDS-PAGE
resulted in the most protein hits of all the
analyses that were performed. A total of 240
proteins were identified from the human IPI
database using default Spectrum Mill param-
eters (Fig. 3). A grand total of 259 proteins
were identified when data form all three meth-
ods were considered.
In order to assess the probability of 
false-positive hits, all MS/MS spectra were
searched against a reversed sequence IPI
database using the same default Spectrum
Mill parameters. This allows one to obtain a
fairly accurate measure of the false-positive
rate of the search data. The results of both
searches shown in Fig. 3 reveal that the esti-
mated number of false-positive protein hits
depends on the number of MS/MS spectra
that are included in the search. Whereas a
rather low percentage of false-positive protein
hits was obtained for the imunodepleted anal-
ysis with no further subfractionation of the
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proteins (two estimated false-positive protein
hits corresponding to a false-positive rate of
2.7%), the number of the estimated false-posi-
tive hits goes up slightly for data files that
contain significantly more MS/MS spectra.
Three and 12 protein hits were obtained when
the AEC and SDS-PAGE subfractionated
MS/MS data were searched against the
reversed sequence IPI database, respectively.
This corresponds to a false-positive rate of 4%
and 5%, respectively. All false-positive hits fall
in the category of “one-hit wonders”; in other
words, only one peptide sequence produced
the respective protein hit. A manual validation
in the case of single peptide hits is therefore
warranted, as there is less confidence in these
assignments. No hits corresponding to “real”
peptide sequences that are present in the IPI
database were found during the reversed
sequence IPI database search.
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Fig. 1. Cerebrospinal fluid (CSF) proteomic workflow. In all cases, CSF was immunodepleted and either under-
went no further protein subfractionation, or anion exchange chromatography resulting in eight salt fractions, or
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) with 146 gel slice fractions. All protein
fractions were further processed by enzymatic digestion followed by shotgun mass spectrometry of the pep-
tide digest mixture. Data-dependent mass spectrometry involved a full scan followed by data-dependent tandem
meass spectrometry (MS/MS) scans of the four most intense peptide ions under dynamic exclusion conditions.
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The number of proteins resulting from
“one-hit wonders” that were deleted from the
list after manual inspection of the MS/MS
spectra were 12, 3, and 0 for the SDS-PAGE-
subfractionated, AEC-subfractionated, and
unfractionated protein runs, respectively.
These numbers are close to the predicted false-
positive rate based on the search against the
reversed sequence human IPI database 
(Fig. 3). A total of 46 common proteins were
identified from all three runs and 95 common
proteins were identified in the AEC- and SDS-
PAGE-subfractionated sample runs (Table 1).
This rather low overlap of protein identifi-
cations from different runs is typical for 
the shotgun mass spectrometry method. In
Table 1, proteins are ranked according to the
number of unique peptides that were identi-
fied for all three runs using the Spectrum Mill
software. Hence, the list is a reflection of pro-
tein abundance in human CSF with high
abundant proteins listed in the upper part of
Table 1.
The proteins found in normal pressure
hydrocephalus CSF can be classified into several
groups based on molecular function,
biological process, and cellular compartment
distribution (Fig. 4 and Table 1). A great
number of these proteins are of low abun-
dance and in many cases represent intracellu-
lar components such as signaling proteins and
transcription factors. These findings indicate
that intracellular contents of cells and tissues
are released into CSF, presumably through
apoptotic and necrotic mechanisms.
Although it is difficult to know how many
proteins are exclusively derived from the brain
because many proteins are likely expressed in
many tissues and therefore could potentially
be introduced into CSF through its exchange
with serum, we now have evidence that many
of the proteins that were identified in CSF are
in fact derived from brain tissue. This is based
on a comparison of the identified CSF proteins
with two recently published human serum
protein databases (10,11). The comparison
revealed that 122 proteins identified in our
CSF analysis were also found during an in-
depth analysis of the human serum proteome
(indicated with a bold font in the “Protein
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Fig. 2. (A) SDS polyacrylamide gel image of the eight salt fractions resulting from anion exchange chromatog-
raphy of immunodepleted cerebrospinal fluid (CSF).The first three lanes after the standards are breakthrough
and wash fractions. (B) SDS polyacrylamide gel image of immunodepleted CSF that was subsequently cut into
146 slices for further processing.The positions of the molecular weight markers are indicated.
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Name” column of Table 1). Of the 122 over-
laps between CSF and serum, 15 proteins
(HSA, transferrin, IgG, fibrinogen, macroglob-
ulin, antitrypsin, C3 complement, apolipopro-
tein A-I, apolipoprotein, -1-acid glycoprotein,
complement factor H, ceruloplasmin, C9
complement, C1q complement, C8 comple-
ment) are considered to be of high abundance
in serum (11). Based on the ranking by Spec-
trum Mill, 5 of these proteins are also of high
abundance in human CSF (macroglobulin, C3
complement, apolipoprotein A–I, complement
factor H, ceruloplasmin; Table 1). Further-
more, 4 proteins (HSA, transferrin, IgG, anti-
trypsin) known to be abundant in CSF (7) had
been depleted by previous immunoaffinity
absorption.
As was the case in our previous analysis (7),
we found proteins with a wide range of iso-
electric points using the shotgun mass spec-
trometry approach (Fig. 5). In order to achieve
a comparable coverage of proteins with 2D-
PAGE analysis, one needs to run several gels
with overlapping pH gradients. This requires
more sample and is often prohibitive when
dealing with human body fluids and tissues.
Some peptides derived from the six proteins
that the Multiple Affinity Removal System
was designed to remove were found in our
analyses. They are most likely derived from
degradation products of these proteins. One
indication that this is indeed the case stems
from the mobility of the protein during SDS-
PAGE, which indicated a smaller molecular
Fig. 3. Results of the mass spectra data analysis using the Spectrum Mill software.The number of proteins that
were identified with default search parameters for all three analyses are plotted for the human international
protein index (IPI) and reversed sequence human IPI database searches.
Table 1
Summary of Proteins That Were Identified in Human CSF From a Patient With Normal Pressure Hydrocephalus Using 
Three Different Sample Preparation Methods 
Unique Molecular Biological Cellular 
peptides Score Protein name function process compartment
63 1073.26 Complement C3 precursor Complement activity Immune response Extracellular
55 980.42 Complement C4 precursor Complement activity Immune response Extracellular
47 792.96 Alpha-2-macroglobulin Protease Inhibitor activity Protein metabolism Extracellular
precursor
46 846.99 Serum albumin precursor Transporter activity Transport Extracellular
41 731.68 Serotransferrin precursor Transporter activity Transport Extracellular
37 633.10 Fibronectin precursor Extracellular matrix Cellular organization Extracellular
protein and biogenesis
32 533.75 Complement factor H Complement activity Immune response Extracellular
28 484.25 Ceruloplasmin precursor Transporter activity Transport Extracellular
27 455.14 Plasminogen precursor Enzymatic activity Protein metabolism Extracellular
26 453.83 Gelsolin precursor Structural constituent of Cellular organization Extracellular
cytoskeleton and biogenesis
25 414.78 Cell adhesion molecule L1-like Cell adhesion molecule Signal transduction; Plasma 
activity Cell communication membrane
24 400.48 Complement component C7 Complement activity Immune response Extracellular
20 342.24 Complement C1r component Complement activity Immune response Extracellular
20 326.75 Complement factor B Complement activity Immune response Extracellular
19 345.99 Vitamin D-binding protein Transporter activity Transport Extracellular
18 305.84 Apolipoprotein E precursor Transporter activity Transport Extracellular
18 288.27 Contactin Cell adhesion molecule Cellular organization Plasma 
activity and biogenesis membrane
18 243.90 Ubiquitin Structural constituent Metabolism Intracellular
of ribosome
17 310.40 Pigment epithelium-derived Serine-type peptidase Signal transduction; Extracellular
factor activity Cell communication
17 297.15 Neuronal cell adhesion Cell adhesion Signal transduction; Plasma 
molecular precursor molecule activity Cell communication membrane
16 289.45 Alpha-1-antitrypsin Transport Transporter activity Extracellular
16 283.16 Apolipoprotein A-I Transporter activity Transport Extracellular
16 272.18 Alpha-1-antichymotrypsin Protease inhibitor activity Protein metabolism Extracellular
15 273.66 Glutamate carboxypeptidase- Transport/Enzymatic Metabolism Extracellular
like protein 2 activity
15 245.36 Fc fragment of IgG binding Receptor activity Signal transduction;  Plasma 
protein Cell communication membrane
14 284.38 Transthyretin precursor Transporter activity Transport Extracellular
14 239.01 Alpha 1B-glycoprotein Unknown Unknown Extracellular
14 235.87 Antithrombin-III Protease Inhibitor Protein metabolism Extracellular
activity
14 220.37 Apolipoprotein A-IV Transporter activity Transport Extracellular
14 213.52 Chitinase-3 like protein 1 Extracellular matrix Cellular organization  Extracellular
protein and biogenesis
13 255.45 Angiotensinogen Peptide hormone Signal transduction; Extracellular
Cell communication
13 242.25 SPARC-like protein 1 Unknown Signal transduction; Extracellular
Cell communication
13 230.07 Neural cell adhesion Cell adhesion Signal transduction; Plasma 
molecule 1 molecule activity Cell communication membrane
13 216.07 Clusterin Complement activity Immune response Extracellular
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(continued)
Immunodepletion Immunodepletion and AEC Immunodepletion and SDS-PAGE
Number Mean Number Mean Number Mean Accession 
of spectra intensity of spectra intensity of spectra intensity Mw pl number
57 5.68e + 007 88 4.76e + 006 326 1.35e + 008 187236.1 6 IPI:IPI00164623.2
45 5.07e + 007 22 4.31e + 006 332 1.27e + 008 192772.5 6.66 IPI:IPI00032258.4
14 2.79e + 007 51 6.10e + 006 217 2.27e + 008 163278.8 5.95 IPI:IPI00032256.1
87 6.05e + 007 262 1.87e + 007 384 1.82e + 008 69367.1 5.47 IPI:IPI00022434.1
10 2.85e + 007 47 8.73e + 006 218 1.92e + 008 77050.4 6.7 IPI:IPI00022463.1
4 2.31e + 007 9 3.40e + 006 76 2.38e + 008 262607.9 5.38 IPI:IPI00022418.1
4 6.95e + 007 30 8.04e + 006 109 3.11e + 008 139126.3 6.19 IPI:IPI00029739.3
31 6.60e + 007 3 6.43e + 006 83 3.12e + 008 122205.8 5.41 IPI:IPI00017601.1
14 3.11e + 007 15 5.39e + 006 59 1.33e + 008 90569.6 7.08 IPI:IPI00019580.1
8 5.63e + 007 27 4.32e + 006 227 2.52e + 008 85697.9 5.72 IPI:IPI00026314.1
9 6.42e + 006 14 3.95e + 006 50 3.46e + 008 136654.8 5.46 IPI:IPI00299059.3
1 2.20e + 006 4 3.69e + 006 65 1.68e + 008 97861.0 6.09 IPI:IPI00296608.4
0 0.00e + 000 2 7.44e + 006 66 1.65e + 008 80174.1 5.82 IPI:IPI00296165.3
0 0.00e + 000 0 0.00e + 000 81 1.09e + 008 85533.4 6.66 IPI:IPI00019591.1
8 2.65e + 007 31 7.53e + 006 142 2.32e + 008 57109.8 5.22 IPI:IPI00298853.4
0 0.00e + 000 38 2.70e + 006 240 2.14e + 008 36154.3 5.52 IPI:IPI00021842.1
1 4.64e + 007 8 3.52e + 006 37 1.43e + 008 113321.0 5.58 IPI:IPI00029751.1
0 0.00e + 000 9 6.08e + 006 18 1.65e + 008 77039.0 7.58 IPI:IPI00220286.1
0 0.00e + 000 11 3.21e + 006 126 2.14e + 008 46342.5 5.90 IPI:IPI00006114.2
4 1.46e + 007 11 4.07e + 006 77 3.19e + 008 143894.4 5.28 IPI:IPI00333776.1
27 4.81e + 007 18 4.68e + 006 61 1.81e + 008 46736.8 5.37 IPI:IPI00305457.3
12 1.59e + 007 83 7.94e + 006 82 3.55e + 008 30778.0 5.27 IPI:IPI00021841.1
0 0.00e + 000 34 6.72e + 006 59 1.48e + 008 48637.3 5.32 IPI:IPI00032215.2
5 3.83e + 006 72 5.83e + 006 51 1.90e + 008 56779.6 5.12 IPI:IPI00064667.1
0 0.00e + 000 3 5.73e + 006 25 4.82e + 007 572099.9 5.03 IPI:IPI00242956.2
27 1.66e + 007 28 4.10e + 006 927 7.70e + 008 15887.1 5.27 IPI:IPI00022432.1
42 2.76e + 007 12 7.95e + 006 48 2.13e + 008 54253.8 5.50 IPI:IPI00216722.1
0 0.00e + 000 17 6.31e + 006 35 1.25e + 008 52602.7 5.95 IPI:IPI00032179.1
6 3.05e + 007 15 2.54e + 006 31 2.97e + 007 45371.3 5.18 IPI:IPI00304273.1
1 2.04e + 007 8 5.43e + 006 40 9.90e + 007 42613.6 8.65 IPI:IPI00002147.3
2 3.30e + 006 1 7.69e + 007 148 1.75e + 008 53154.5 5.60 IPI:IPI00032220.1
8 5.42e + 006 66 3.88e + 006 19 1.86e + 008 75216.1 4.66 IPI:IPI00296777.3
0 0.00e + 000 3 6.02e + 006 53 1.22e + 008 83770.5 4.77 IPI:IPI00220737.1
0 0.00e + 000 10 4.30e + 006 208 1.21e + 008 52494.9 5.89 IPI:IPI00291262.3
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13 213.68 Splice isoform 2 of Protease Inhibitor activity Unknown Extracellular
Inter-alpha-trypsin 
inhibitor heavy chain 
H4 precursor
12 213.21 Fibulin-1 Extracellular matrix protein Cellular organization Extracellular
and biogenesis
12 211.17 Hemopexin Transporter activity Transport Extracellular
12 177.50 Procollagen C-proteinase Extracellular matrix protein Cellular organization Extracellular
enhancer protein and biogenesis
11 194.54 Plasma protease C1 inhibitor Protease Inhibitor activity Protein metabolism Extracellular
11 193.63 Alpha-2-HS-glycoprotein Unknown Signal transduction; Extracellular
Cell communication
11 181.66 Ectonucleotide Phosphoric diester Metabolism; Energy Extracellular
pyrophosphatase/ hydrolase activity pathways
phosphodiesterase 2
11 180.82 Afamin Structural molecule activity Cellular organization Extracellular
and biogenesis
11 169.91 Complement C1s Complement activity Immune response Extracellular
component
10 175.87 Histidine-rich Transporter activity Transport Extracellular
glycoprotein
10 175.59 Prothrombin Blood coagulation factor Protein metabolism Extracellular
activity
10 175.02 Cystatin C Protease Inhibitor activity Protein metabolism Extracellular
10 171.60 Tetranectin Unknown Unknown Extracellular
10 170.58 Amyloid-like protein 1 Transcription regulator Signal transduction; Plasma membrane
precursor activity Cell communication
10 166.36 Calsyntenin-1 calcium ion binding homophilic Plasma 
cell adhesion membrane
10 164.57 Zinc-alpha-2- Unknown Immune response Extracellular
glycoprotein
10 160.56 Neurocan core protein Extracellular matrix protein Signal transduction; Extracellular
Cell communication
10 147.15 Protein kinase C-binding calcium ion binding cell adhesion Extracellular
protein NELL2
9 156.14 Kallikrein 6 Serine-type peptidase Protein metabolism Cytoplasm
activity
9 155.23 Splice Isoform: LMW of Blood coagulation Protein metabolism Extracellular
Kininogen factor activity
9 154.44 AMBP protein Unknown Immune response Extracellular
9 151.51 Dihydropyridine-sensitive Voltage-gated ion channel Transport Sarcoplasmic 
L-type activity Reticulum
9 150.84 Contactin 2 Cell adhesion molecule Signal transduction; Plasma membrane
activity Cell communication
9 148.54 Complement factor I Unknown Immune response Extracellular
9 144.92 Keratin Structural constituent of Cellular organization Cytoplasm
cytoskeleton and biogenesis
9 143.00 Amyloid beta A4 protein Receptor activity Signal transduction; Plasma membrane
Cell communication
9 136.24 Fibrinogen alpha/alpha-E Blood coagulation factor Protein metabolism Extracellular
chain precursor activity
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0 0.00e + 000 0 0.00e + 000 25 1.25e + 008 101242.5 6.21 IPI:IPI00218192.1
0 0.00e + 000 0 0.00e + 000 34 8.11e + 007 77261.8 5.07 IPI:IPI00296534.1
14 3.83e + 007 53 1.12e + 007 147 1.40e + 008 51676.7 6.43 IPI:IPI00022488.1
1 1.56e + 007 0 0.00e + 000 38 8.46e + 007 47972.8 7.55 IPI:IPI00299738.1
6 1.87e + 007 38 4.74e + 006 28 1.51e + 008 55154.5 5.97 IPI:IPI00291866.1
13 1.64e + 007 61 1.32e + 007 25 1.40e + 008 39324.9 5.36 IPI:IPI00022431.1
6 4.45e + 007 0 0.00e + 000 18 8.04e + 007 99004.2 7.43 IPI:IPI00156171.2
0 0.00e + 000 2 3.30e + 006 18 9.99e + 007 69069.6 5.58 IPI:IPI00019943.1
0 0.00e + 000 13 4.26e + 006 23 1.45e + 008 76684.9 4.86 IPI:IPI00017696.1
8 1.33e + 007 5 4.03e + 006 18 9.29e + 007 59578.6 7.03 IPI:IPI00022371.1
8 3.59e + 007 3 2.48e + 006 25 1.81e + 008 70037.3 5.24 IPI:IPI00019568.1
3 3.06e + 008 0 0.00e + 000 299 1.26e + 009 15799.3 8.75 IPI:IPI00032293.1
0 0.00e + 000 2 4.28e + 006 51 6.81e + 007 22567.0 5.80 IPI:IPI00009028.1
22 7.93e + 006 0 0.00e + 000 48 1.41e + 008 72176.8 5.37 IPI:IPI00020012.2
6 1.87e + 007 38 4.74e + 006 28 1.51e + 008 55154.5 5.97 IPI:IPI00291866.1
13 1.64e + 007 61 1.32e + 007 25 1.40e + 008 39324.9 5.36 IPI:IPI00022431.1
6 4.45e + 007 0 0.00e + 000 18 8.04e + 007 99004.2 7.43 IPI:IPI00156171.2
0 0.00e + 000 2 3.30e + 006 18 9.99e + 007 69069.6 5.58 IPI:IPI00019943.1
0 0.00e + 000 13 4.26e + 006 23 1.45e + 008 76684.9 4.86 IPI:IPI00017696.1
8 1.33e + 007 5 4.03e + 006 18 9.29e + 007 59578.6 7.03 IPI:IPI00022371.1
8 3.59e + 007 3 2.48e + 006 25 1.81e + 008 70037.3 5.24 IPI:IPI00019568.1
3 3.06e + 008 0 0.00e + 000 299 1.26e + 009 15799.3 8.75 IPI:IPI00032293.1
0 0.00e + 000 2 4.28e + 006 51 6.81e + 007 22567.0 5.80 IPI:IPI00009028.1
22 7.93e + 006 0 0.00e + 000 48 1.41e + 008 72176.8 5.37 IPI:IPI00020012.2
0 0.00e + 000 7 4.30e + 006 32 1.41e + 008 109793.3 4.77 IPI:IPI00007257.1
0 0.00e + 000 6 3.78e + 006 46 4.13e + 007 34258.9 5.58 IPI:IPI00166729.1
0 0.00e + 000 0 0.00e + 000 17 8.76e + 007 142973.9 5.20 IPI:IPI00159927.1
0 0.00e + 000 1 4.32e + 006 25 1.90e + 008 91347.2 5.40 IPI:IPI00015260.1
0 0.00e + 000 6 4.18e + 006 71 5.60e + 007 26855.9 6.91 IPI:IPI00023845.1
0 0.00e + 000 2 3.82e + 006 32 1.23e + 008 47883.5 6.29 IPI:IPI00215894.1
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8 155.17 Chromogranin A Unknown Signal transduction; Extracellular
Cell communication
8 150.27 Prostaglandin-H2 D-isomerase Catalytic activity Metabolism; Energy Cytoplasm
pathways
8 141.03 Apolipoprotein D Transporter activity Transport Extracellular
8 139.15 Neural cell adhesion molecule 2 Cell adhesion molecule Cellular organization Plasma 
activity and biogenesis membrane
8 133.09 Keratin, type II cuticular HB3 Structural constituent of Cellular organization Cytoplasm
cytoskeleton and biogenesis
8 130.72 N-acetyllactosaminide beta-1,3-N- Enzymatic activity Biosynthesis Plasma 
acetylglucosaminyltransferase membrane
8 130.61 Inter-alpha-trypsin inhibitor Protease Inhibitor activity Unknown Extracellular
heavy chain H2
8 119.64 Apolipoprotein B-100 Transporter activity Transport Endoplasmic 
reticulum
7 137.33 Beta-2-glycoprotein I Transporter activity Transport Extracellular
7 136.99 Fibrinogen gamma chain Blood coagulation factor Protein metabolism Extracellular
activity
7 119.14 Basement membrane-specific Extracellular matrix protein Cellular organization Extracellular
heparan sulfate and biogenesis
proteoglycan
7 113.05 Multiple EGF-like-domain Unknown Unknown Membrane 
protein 4 protein
7 112.89 Complement component Complement activity Immune response Extracellular
C8 gamma chain
7 111.94 Immunoglobulin superfamily, Protein binding Cell proliferation Integral to 
member 8 membrane
7 108.53 Type I hair keratin 1 Structural constituent Cellular organization Cytoplasm
of cytoskeleton and biogenesis
6 117.44 Phosphatidylethanolamine- Protease Inhibitor activity Signal transduction; Cytoplasm
binding protein Cell communication
6 112.06 Secretogranin III Peptide hormone Signal transduction; Extracellular
Cell communication
6 111.66 Osteopontin Cell adhesion molecule Cellular organization Extracellular
activity and biogenesis
6 108.39 Inter-alpha-trypsin inhibitor Protease Inhibitor activity Protein metabolism Extracellular
heavy chain H1
6 107.58 Monocyte differentiation Receptor activity Immune response Plasma 
antigen CD14 membrane
6 104.08 Immunoglobulin superfamily Cell adhesion molecule Signal transduction; Plasma 
activity Cell communication membrane
6 102.38 Plasma retinol-binding protein Transporter activity Transport Extracellular
6 98.27 Splice isoform 2 of Protein- Receptor activity Signal transduction; Plasma 
tyrosine phosphatase non- Cell communication membrane
receptor type substrate 1 
precursor
6 92.71 Protein FAM3C Receptor activity Unknown Extracellular
6 92.62 Neogenin Receptor activity Signal transduction; Plasma 
Cell communication membrane
6 92.56 Chondroitin sulfate Extracellular matrix protein Signal transduction; Extracellular
proteoglycan BEHAB Cell communication
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0 0.00e + 000 1 2.33e + 006 27 9.67e + 007 38999.7 5.91 IPI:IPI00022426.1
0 0.00e + 000 0 0.00e + 000 14 1.16e + 008 123184.0 4.96 IPI:IPI00306196.1
0 0.00e + 000 0 0.00e + 000 15 2.09e + 008 113393.9 7.35 IPI:IPI00024966.1
0 0.00e + 000 0 0.00e + 000 22 4.09e + 007 65720.7 7.38 IPI:IPI00291867.3
0 0.00e + 000 0 0.00e + 000 13 2.70e + 007 66067.0 8.82 IPI:IPI00220327.1
11 2.01e + 007 10 2.93e + 006 17 8.84e + 007 86943.8 4.72 IPI:IPI00006608.1
5 1.19e + 007 2 2.89e + 006 11 4.21e + 007 94973.5 5.65 IPI:IPI00021885.1
5 2.41e + 007 65 6.71e + 006 1 7.66e + 006 50730.7 4.56 IPI:IPI00290315.3
92 9.50e + 006 24 1.31e + 007 280 1.39e + 008 21028.9 8.37 IPI:IPI00013179.1
0 0.00e + 000 2 5.19e + 006 81 7.62e + 007 21275.7 5.20 IPI:IPI00006662.1
0 0.00e + 000 0 0.00e + 000 16 7.61e + 007 93046.7 5.33 IPI:IPI00376427.1
0 0.00e + 000 0 0.00e + 000 11 4.61e + 007 54214.8 5.20 IPI:IPI00297795.3
3 1.92e + 007 0 0.00e + 000 50 1.16e + 008 47119.3 6.56 IPI:IPI00009997.1
3 3.27e + 007 0 0.00e + 000 11 1.51e + 008 106596.2 5.75 IPI:IPI00305461.1
0 0.00e + 000 1 4.29e + 006 7 8.19e + 007 515565.2 6.59 IPI:IPI00022229.1
0 0.00e + 000 0 0.00e + 000 35 1.25e + 008 38298.4 8.37 IPI:IPI00298828.1
9 8.44e + 006 3 2.06e + 006 26 1.08e + 008 51511.9 5.24 IPI:IPI00021891.5
0 0.00e + 000 1 2.80e + 006 10 4.96e + 007 468827.8 6.03 IPI:IPI00024284.2
0 0.00e + 000 0 0.00e + 000 8 1.22e + 008 305565.3 6.57 IPI:IPI00027310.3
3 1.57e + 007 0 0.00e + 000 14 3.57e + 007 22219.5 8.87 IPI:IPI00011261.1
0 0.00e + 000 0 0.00e + 000 13 1.69e + 007 65034.6 9.15 IPI:IPI00056478.1
0 0.00e + 000 0 0.00e + 000 13 8.28e + 007 47237.3 4.65 IPI:IPI00383759.1
1 5.09e + 007 0 0.00e + 000 16 3.55e + 007 21056.9 7.84 IPI:IPI00219446.1
8 1.40e + 007 47 7.06e + 006 3 7.21e + 007 52977.5 4.94 IPI:IPI00292071.3
19 7.81e + 006 36 1.31e + 007 61 5.49e + 007 35422.9 4.35 IPI:IPI00021000.1
0 0.00e + 000 0 0.00e + 000 9 1.29e + 008 101389.7 6.32 IPI:IPI00292530.1
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6 92.46 Metalloproteinase inhibitor 1 Extracellular matrix protein Cellular organization Extracellular
and biogenesis
6 89.21 Mimecan Growth factor activity Signal transduction; Extracellular
Cell communication
5 95.80 Fructose-bisphosphate Aldolase activity Metabolism; Energy Cytoplasm
aldolase C pathways
5 95.16 Insulin-like growth factor Cell adhesion molecule Signal transduction; Extracellular
binding protein 2 activity Cell communication
5 94.78 Neural-cadherin Cell adhesion molecule Signal transduction; Plasma 
activity Cell communication membrane
5 93.22 Aspartate aminotransferase Unknown Metabolism; Energy Cytoplasm
pathways
5 92.45 Superoxide dismutase Superoxide dismutase Metabolism; Energy Cytoplasm
activity pathways
5 92.12 Fibrinogen beta chain Blood coagulation factor Protein metabolism Extracellular
activity
5 90.84 Hypothetical protein Enzyme activity Unknown Extracellular
KIAA0830
5 89.55 Dickkopf related protein-3 Receptor binding Signal transduction; Extracellular
Cell communication
5 89.30 Coagulation factor XII Blood coagulation factor Protein metabolism Extracellular
activity
5 87.99 Neuronal pentraxin I Transporter activity Signal transduction; Extracellular
Cell communication




5 86.31 Galectin 3 binding protein Extracellular matrix protein Immune response Extracellular
5 85.46 Alpha-1-acid Unknown Immune response Extracellular
glycoprotein 1
5 83.24 Serum paraoxonase Hydrolase activity, acting Metabolism; Energy Extracellular
on ester bonds pathways
5 81.19 Protein tyrosine phosphatase, tor signaling protein Signal transduction; Plasma 
receptor type, sigma tyrosine phosphatase Cell communication membrane
isoform 2
5 78.79 EGF-containing fibulin-like Extracellular matrix protein Cellular organization Extracellular
extracellular matrix protein and biogenesis
1 isoforr
5 75.50 Hypothetical protein Unknown Unknown Unknown
5 71.25 Cathepsin D Enzymatic activity: Protein metabolism Lysosome
ysteine-type
4 76.81 Ganglioside GM2 activator Transporter activity Metabolism; Energy Lysosome
pathways
4 76.54 Complement factor D precursor Serine-type peptidase Immune response Extracellular
activity
4 73.76 Epididymal secretory protein E1 Transporter activity Metabolism; Energy Lysosome
pathways
4 73.43 Complement component C6 Complement activity Immune response Extracellular
4 71.81 Proprotein convertase subtilisin Peptide hormone Signal transduction; Extracellular
Cell communication
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0 0.00e + 000 2 3.65e + 006 45 1.60e + 008 40076.4 5.20 IPI:IPI00029260.2
0 0.00e + 000 0 0.00e + 000 15 4.05e + 007 42785.5 5.89 IPI:IPI00176427.1
0 0.00e + 000 0 0.00e + 000 13 4.16e + 007 23044.2 5.27 IPI:IPI00022420.2
2 3.318 + 007 7 3.45e + 006 9 3.38e + 007 55240.4 6.29 IPI:IPI00216031.1
3 1.51e + 007 0 0.00e + 000 21 2.37e + 007 24680.6 7.75 IPI:IPI00021923.1
0 0.00e + 000 0 0.00e + 000 6 8.20e + 007 159960.3 5.95 IPI:IPI00023814.1
0 0.00e + 000 2 2.29e + 006 10 4.14e + 007 99148.7 4.57 IPI:IPI00107634.2
0 0.00e + 000 0 0.00e + 000 23 7.95e + 007 23171.0 8.47 IPI:IPI00032292.1
0 0.00e + 000 0 0.00e + 000 20 2.27e + 007 33922.4 5.22 IPI:IPI00025465.1
0 0.00e + 000 0 0.00e + 000 15 4.46e + 007 39456.1 6.47 IPI:IPI00216976.1
3 1.95e + 007 0 0.00e + 000 19 5.85e + 007 35137.8 6.90 IPI:IPI00297284.1
0 0.00e + 000 6 3.44e + 006 21 1.23e + 008 99851.9 4.49 IPI:IPI00290085.1
0 0.00e + 000 0 0.00e + 000 7 5.23e + 007 46247.7 6.59 IPI:IPI00219029.1
0 0.00e + 000 37 1.37e + 007 9 2.09e + 007 15935.8 5.68 IPI:IPI00218733.1
0 0.00e + 000 0 0.00e + 000 23 4.95e + 007 55928.5 7.95 IPI:IPI00298497.3
0 0.00e + 000 5 4.89e + 006 16 2.79e + 007 59385.1 5.81 IPI:IPI00001952.2
0 0.00e + 000 12 6.85e + 006 25 1.02e + 008 38291.4 4.52 IPI:IPI00002714.1
1 2.06e + 007 0 0.00e + 000 8 1.25e + 008 67818.6 9.39 IPI:IPI00019581.1
0 0.00e + 000 0 0.00e + 000 13 4.27e + 007 47122.6 5.84 IPI:IPI00220562.1
0 0.00e + 000 0 0.00e + 000 13 4.08e + 007 16840.6 9.18 IPI:IPI00029699.1
0 0.00e + 000 0 0.00e + 000 12 9.18e + 007 65331.4 4.99 IPI:IPI00023673.1
27 9.08e + 007 12 6.43e + 006 26 5.46e + 007 23511.7 5.00 IPI:IPI00022429.1
0 0.00e + 000 0 0.00e + 000 12 3.98e + 007 39731.5 4.96 IPI:IPI00218732.1
0 0.00e + 000 3 1.90e + 006 9 6.23e + 007 212539.7 6.35 IPI:IPI00107764.1
0 0.00e + 000 0 0.00e + 000 26 5.86e + 007 52066.8 4.90 IPI:IPI00002365.1
0 0.00e + 000 0 0.00e + 000 8 5.99e + 007 54154.4 6.21 IPI:IPI00061977.1
0 0.00e + 000 0 0.00e + 000 13 5.99e + 007 44552.5 6.11 IPI:IPI00011229.1
4 5.56e + 006 2 4.67e + 006 8 3.62e + 007 20822.4 4.76 IPI:IPI00018236.1
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4 71.24 Complement C1q Complement activity Immune response Extracellular
subcomponent
4 69.91 Insulin-like growth factor  Cell adhesion molecule Signal transduction; Extracellular
binding protein 7 activity Cell communication
4 69.58 Ig kappa chain C region antigen binding immune response Unknown
4 69.07 hypothetical protein Unknown Unknown Unknown
MGC45438
4 68.87 Actin, cytoplasmic 1 Structural constituent of Cellular organization Cytoplasm
cytoskeleton and biogenesis
4 68.86 Peptidyl-prolyl cis-trans Chaperone activity Unknown Cytoplasm
isomerase A
4 68.72 Immunoglobulin superfamily, Cell adhesion molecule Signal transduction; Plasma 
member 4B activity Cell communication membrane
4 68.54 Beta-2-microglobulin ass II receptor activity  Immune response Extracellular
MHC class I receptor
4 65.99 CD163 antigen isoform b Unknown Immune response Plasma 
membrane
4 63.80 Vitronectin Extracellular matrix Cellular organization Extracellular
protein and biogenesis
4 61.16 Complement C5 beta chain Complement protein Cellular organization Extracellular
activity and biogenesis
4 60.61 Extracellular matrix protein 1 Extracellular matrix Cellular organization Extracellular
protein and biogenesis
4 59.10 SPARC precursor Transport Signal transduction; Extracellular
Cell communication
4 58.60 Complement C1q Immune response Immune response Extracellular
subcomponent
4 57.60 Glyceraldehyde-3- Catalytic activity Metabolism; Energy Cytoplasm
phosphate pathways
dehydrogenase
4 57.13 Neurotrimin Cell adhesion molecule Signal transduction; Plasma 
activity Cell communication membrane
4 56.93 Peptidyl-glycine alpha- Transport Metabolism Plasma 
amidating monooxygenase membrane
precursor
3 55.98 Neurexin 2-alpha precursor Cell adhesion molecule Signal transduction; Plasma 
activity Cell communication membrane
3 55.12 Insulin-like growth factor Cell adhesion molecule Signal transduction; Extracellular
binding protein 6 activity Cell communication
3 54.59 Extracellular superoxide Superoxide dismutase Metabolism; Energy Extracellular
dismutase activity pathways
3 53.90 Collagen alpha 1(XVIII) Extracellular matrix Cellular organization Extracellular
protein and biogenesis
3 53.20 Hypothetical protein Unknown Unknown Unknown
3 52.64 Insulin-like growth factor II Growth factor activity Signal transduction; Extracellular
Cell communication
3 52.51 Complement C1q  Complement activity Complement activity Extracellular
subcomponent, B chain 
precursor
3 50.84 Retinoic acid receptor responder Unknown Signal transduction; Plasma 
protein Cell communication membrane
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3 3.95e + 007 4 4.63e + 006 2 2.31e + 007 27004.1 6.85 IPI:IPI00019579.1
2 1.30e + 007 0 0.00e + 000 32 2.49e + 007 19657.9 6.95 IPI:IPI00301579.2
0 0.00e + 000 0 0.00e + 000 8 1.34e + 008 104844.8 6.11 IPI:IPI00009920.1
0 0.00e + 000 5 7.25e + 006 8 3.63e + 007 27372.5 6.24 IPI:IPI00002280.1
0 0.00e + 000 0 0.00e + 000 7 2.77e + 007 26016.7 9.34 IPI:IPI00022392.1
0 0.00e + 000 9 4.13e + 006 10 2.06e + 007 29130.5 8.06 IPI:IPI00016915.1
0 0.00e + 000 1 5.95e + 006 18 4.13e + 007 11608.9 5.53 IPI:IPI00004574.1
0 0.00e + 000 0 0.00e + 000 8 4.69e + 007 48766.4 5.70 IPI:IPI00296168.1
0 0.00e + 000 9 4.04e + 006 8 5.02e + 007 41737.0 5.29 IPI:IPI00021439.1
0 0.00e + 000 0 0.00e + 000 6 1.30e + 007 17881.4 9.14 IPI:IPI00006664.4
0 0.00e + 000 2 7.32e + 006 14 4.43e + 007 47021.2 5.07 IPI:IPI00009619.1
23 2.57e + 007 49 8.26e + 006 9 1.60e + 009 13714.6 6.07 IPI:IPI00004656.1
0 0.00e + 000 0 0.00e + 000 4 1.31e + 008 125353.4 5.69 IPI:IPI00104074.3
0 0.00e + 000 0 0.00e + 000 15 2.30e + 008 54305.9 5.47 IPI:IPI00298971.1
0 0.00e + 000 0 0.00e + 000 5 6.16e + 007 188332.4 5.01 IPI:IPI00032291.1
0 0.00e + 000 7 2.76e + 006 3 6.39e + 007 60704.5 6.19 IPI:IPI00003351.1
1 1.80e + 007 2 4.35e + 006 1 2.75e + 007 34632.4 4.66 IPI:IPI00014572.1
0 0.00e + 000 0 0.00e + 000 10 2.36e + 008 25773.8 8.33 IPI:IPI00022394.2
0 0.00e + 000 1 3.51e + 006 7 4.49e + 007 36053.4 9.30 IPI:IPI00219018.1
1 1.34e + 007 1 3.26e + 006 4 6.99e + 007 37971.7 6.01 IPI:IPI00009764.1
0 0.00e + 000 0 0.00e + 000 4 2.03e + 007 108403.7 5.83 IPI:IPI00177543.4
0 0.00e + 000 0 0.00e + 000 6 2.14e + 007 184983.0 5.55 IPI:IPI00007921.1
17 7.39e + 007 13 5.70e + 006 20 4.54e + 007 25322.6 7.94 IPI:IPI00029235.1
0 0.00e + 000 0 0.00e + 000 8 2.37e + 007 25881.1 6.32 IPI:IPI00027827.1
0 0.00e + 000 0 0.00e + 000 10 1.69e + 007 153827.4 5.40 IPI:IPI00022822.2
0 0.00e + 000 0 0.00e + 000 5 2.42e + 007 214847.3 6.77 IPI:IPI00374563.1
0 0.00e + 000 0 0.00e + 000 4 6.48e + 007 20140.5 9.50 IPI:IPI00001611.1
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3 49.69 Insulin-like growth factor Cell adhesion molecule Signal transduction; Extracellular
binding protein 4 activity Cell communication
3 49.25 L-lactate dehydrogenase B chain Catalytic activity Metabolism; Energy Cytoplasm
pathways
3 48.49 Peptidoglycan recognition Receptor activity Immuno response Intracellular/
protein 2 Membrane 
protein
3 48.37 Sex hormone-binding globulin Transporter activity Transport Extracellular
3 47.86 hypothetical protein MGC33530 Protein binding Cell adhesion/ Plasma 
neurogenesis membrane
3 47.26 hypothetical protein MGC33530 Unknown Unknown Unknown
3 47.14 Metalloproteinase inhibitor 2 Extracellular matrix Cellular organization Extracellular
protein and biogenesis
3 46.83 Plasma glutathione peroxidase Peroxidase activity Metabolism; Energy Extracellular
pathways
3 46.04 Hypothetical protein FLJ10320 Cell adhesion molecule Signal transduction; Extracellular
activity Cell communication
3 43.34 Protein-tyrosine phosphatase tor signaling protein Signal transduction; Plasma 
delta precursor tyrosine phosphatase Cell communication membrane
3 39.26 Leucine-rich alpha-3- Unknown Unknown Plasma 
glycoprotein membrane
3 38.51 Complement C2 Complement protein Immune response Extracellular
activity
3 32.49 similar to Serine/threonine Protein serine/threonine Signal transduction; Cytoplasm
protein kinase PRKK\ kinase activity Cell communication
3 32.46 Transforming growth Receptor binding Signal transduction; Extracellular
factor-beta induced Cell communication
2 43.72 Secretogranin I Peptide hormone Signal transduction; Extracellular
Cell communication
2 41.91 Neurexin 1-alpha Cell adhesion molecule Signal transduction; Plasma 
activity Cell communication membrane
2 41.71 Proteoglycan 4 Unclassified cell proliferation Extracellular
2 41.36 Splice isoform 1 of O94856 Cell adhesion molecule Signal transduction; Plasma 
Neurofascin precursor activity Cell communication membrane




2 38.21 Lysozyme C Hydrolase activity Metabolism; Energy Extracellular
pathways
2 38.12 Thy-1 membrane glycoprotein Unknown Immune response Plasma 
membrane
2 38.10 Cartilage oligomeric matrix Extracellular matrix Cellular organization Extracellular
protein protein and biogenesis
2 37.91 Carboxypeptidase H Enzymatic activity metabolism Plasma 
membrane
2 35.75 Chitinase-3 like protein 1 Signal transduction; Plasma
Cell communication membrane
Transport Extracellular
2 35.47 Dystroglycan Cell adhesion molecule Metabolism Extracellular 
activity
352 __________________________________________________________________________ Maccarrone et al.
Clinical Proteomics _______________________________________________________________ Volume 1, 2004
(continued)
Immunodepletion Immunodepletion and AEC Immunodepletion and SDS-PAGE
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of spectra intensity of spectra intensity of spectra intensity Mw pl number
0 0.00e + 000 0 0.00e + 000 15 2.86e + 007 26703.9 8.85 IPI:IPI00218746.1
2 1.69e + 007 0 0.00e + 000 12 2.19e + 007 18617.7 8.99 IPI:IPI00019176.1
2 8.12e + 006 0 0.00e + 000 5 2.38e + 008 27934.2 6.87 IPI:IPI00305380.3
0 0.00e + 000 0 0.00e + 000 8 3.22e + 007 36638.7 5.72 IPI:IPI00219217.1
0 0.00e + 000 1 3.61e + 006 2 7.15e + 007 62217.3 7.64 IPI:IPI00163207.1
0 0.00e + 000 0 0.00e + 000 5 2.58e + 007 43779.4 5.83 IPI:IPI00023019.1
0 0.00e + 000 3 2.96e + 006 3 3.99e + 007 37308.6 8.87 IPI:IPI00013303.1
0 0.00e + 000 0 0.00e + 000 6 4.90e + 006 27049.6 8.87 IPI:IPI00290411.1
0 0.00e + 000 0 0.00e + 000 4 6.78e + 007 24399.4 6.48 IPI:IPI00027166.1
0 0.00e + 000 0 0.00e + 000 5 5.38e + 007 25505.6 7.80 IPI:IPI00026199.1
0 0.00e + 000 1 2.59e + 006 2 5.57e + 007 44861.6 5.31 IPI:IPI00018073.1
0 0.00e + 000 1 4.72e + 006 3 3.61e + 007 214761.0 6.10 IPI:IPI00011642.1
0 0.00e + 000 2 6.84e + 006 6 9.36e + 007 38178.1 5.66 IPI:IPI00022417.2
1 1.09e + 007 1 7.46e + 006 1 3.95e + 007 83268.3 7.57 IPI:IPI00303963.1
3 4.84e + 007 0 0.00e + 000 0 0.00e + 000 141149.6 11.51 IPI:IPI00399428.1
0 0.00e + 000 0 0.00e + 000 3 5.01e + 007 74681.3 7.37 IPI:IPI00018219.1
5 7.10e + 006 33 5.89e + 006 0 0.00e + 000 78246.6 5.02 IPI:IPI00006601.3
0 0.00e + 000 0 0.00e + 000 2 6.93e + 007 161883.8 5.61 IPI:IPI00006314.1
0 0.00e + 000 0 0.00e + 000 2 6.89e + 007 151091.9 10.15 IPI:IPI00024825.1
0 0.00e + 000 1 5.36e + 006 2 1.00e + 008 137619.5 5.73 IPI:IPI00394652.1
0 0.00e + 000 0 0.00e + 000 17 2.36e + 007 17644.4 8.98 IPI:IPI00014048.1
0 0.00e + 000 0 0.00e + 000 6 4.27e + 008 16537.1 9.28 IPI:IPI00019038.1
11 5.59e + 007 0 0.00e + 000 8 1.84e + 007 17934.8 9.16 IPI:IPI00022892.2
0 0.00e + 000 0 0.00e + 000 2 1.06e + 008 82832.9 4.35 IPI:IPI00028030.1
0 0.00e + 000 0 0.00e + 000 6 8.26e + 007 53150.9 4.98 IPI:IPI00031121.1
0 0.00e + 000 0 0.00e + 000 4 5.60e + 007 43501.0 7.77 IPI:IPI00019533.1
0 0.00e + 000 0 0.00e + 000 10 3.18e + 007 97581.2 9.36 IPI:IPI00028911.1
0 0.00e + 000 0 0.00e + 000 2 4.85e + 007 479394.8 5.00 IPI:IPI00302641.1
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2 35.44 Protocadherin Fat 2 Transport activity Immune response Extracellular
2 35.43 Cystatin M Protease Inhibitor Immune response Plasma
activity membrane
2 34.62 Complement component C9 Complement protein Cellular organization Extracellular
activity and biogenesis
2 34.44 Semaphorin 7A Receptor activity Signal transduction; Plasma 
Cell communication membrane
2 34.44 Nidogen-2 Extracellular matrix Cellular organization Extracellular
protein and biogenesis
2 34.42 Oligodendrocyte-myelin Cell adhesion molecule Signal transduction; Plasma 
glycoprotein activity Cell communication membrane
2 34.34 Alpha 2 type I collagen Extracellular matrix Cellular organization Extracellular
protein and biogenesis
2 34.14 CD59 glycoprotein Receptor activity Immune response Plasma 
membrane
2 33.81 Neuroendocrine protein 7B2 Chaperone activity Signal transduction Extracellular
2 33.34 Microfibril-associated Protein binding Cell adhesion Extracellular
glycoprotein 4
2 33.17 Neuronal pentraxin receptor Receptor molecule activity Immune response Plasma 
membrane
2 32.10 DJ68D18.2.5 Transport activity Immune response Plasma 
membrane
2 32.06 Corticosteroid-binding globulin Transport Transporter activity Extracellular
2 31.75 Neuronal growth regulator 1 Adhesion molecule activity: Signal transduction Extracellular
Neural cell
2 31.68 Seizure related 6 homolog Unknown Signal transduction; Membrane 
Cell communication protein
2 31.61 Pyruvate kinase 3 isoform 2 Catalytic activity Metabolism; Energy Cytoplasm
pathways
2 30.54 Serum amyloid A-4 protein Transporter activity Transport Extracellular
2 30.12 Calreticulin Chaperone activity Protein metabolism Endoplasmic 
Reticulum
2 30.11 Ecto-ADP-ribosyltransferase 3 Catalytic activity Protein metabolism Plasma 
membrane
2 29.52 Hypothetical protein protein binding Immuno response Extracellular
2 29.40 Vitamin K-dependent protein C Blood coagulation factor Protein metabolism extracellular
activity
2 29.27 Cadherin-13 precursor Cell adhesion molecule Cellular organization Plasma 
activity and biogenesis membrane
2 27.95 Complement component C8 complement activity immuno response Plasma 
membrane
2 26.41 Collagen alpha 1(VI) chain Extracellular matrix protein Cellular organization Extracellular
and biogenesis
2 26.32 Keratin, type I cuticular HA6 Structural molecule activity Cellular organization Extracellular
and biogenesis
2 25.64 similar to contains Binding protein Immune response Extracellular
transmembrane (TM) region
2 25.25 Ribonuclease K6 Enzymatic activity: Of nucleobase, Extracellular
Ribonuclease activity nucleoside, 
nucleotide
and nucleic acid 
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0 0.00e + 000 0 0.00e + 000 4 1.12e + 008 16511.2 7.00 IPI:IPI00019954.1
0 0.00e + 000 0 0.00e + 000 5 6.65e + 007 63173.8 5.42 IPI:IPI00022395.1
0 0.00e + 000 2 5.98e + 006 2 6.92e + 007 74824.2 6.58 IPI:IPI00025257.1
0 0.00e + 000 0 0.00e + 000 2 1.11e + 007 151395.8 5.06 IPI:IPI00028908.3
0 0.00e + 000 9 4.85e + 006 0 0.00e + 000 49608.2 7.80 IPI:IPI00295832.1
0 0.00e + 000 0 0.00e + 000 2 1.14e + 008 129288.4 9.74 IPI:IPI00164755.2
0 0.00e + 000 0 0.00e + 000 4 7.08e + 006 14177.4 5.18 IPI:IPI00011302.1
3 5.80e + 006 2 2.05e + 006 0 0.00e + 000 23729.8 5.49 IPI:IPI00008944.2
0 0.00e + 000 0 0.00e + 000 2 1.20e + 007 28648.4 5.21 IPI:IPI00022792.3
0 0.00e + 000 14 6.15e + 006 8 2.60e + 007 52718.4 5.72 IPI:IPI00031289.1
1 8.49e + 006 5 3.64e + 006 0 0.00e + 000 50727.8 5.18 IPI:IPI00021230.2
3 1.24e + 007 1 3.51e + 006 2 5.75e + 007 45141.1 5.64 IPI:IPI00027482.1
0 0.00e + 000 0 0.00e + 000 6 6.18e + 007 38779.5 5.81 IPI:IPI00176221.1
1 3.20e + 007 0 0.00e + 000 3 2.63e + 008 107585.8 5.05 IPI:IPI00154734.1
0 0.00e + 000 0 0.00e + 000 5 3.39e + 007 58293.6 8.66 IPI:IPI00220644.5
0 0.00e + 000 2 2.23e + 006 6 2.06e + 007 14806.8 9.19 IPI:IPI00019399.1
1 2.21e + 007 0 0.00e + 000 2 1.26e + 008 48141.8 4.29 IPI:IPI00020599.1
0 0.00e + 000 2 5.22e + 006 3 2.78e + 007 43923.5 5.64 IPI:IPI00013682.2
0 0.00e + 000 1 4.31e + 006 1 8.78e + 007 67921.9 6.00 IPI:IPI00101462.1
0 0.00e + 000 0 0.00e + 000 2 9.58e + 006 52071.6 5.60 IPI:IPI00021817.1
0 0.00e + 000 1 3.90e + 006 4 1.31e + 007 78287.2 4.77 IPI:IPI00024046.1
2 1.45e + 007 0 0.00e + 000 3 3.13e + 007 65163.6 5.74 IPI:IPI00011252.1
0 0.00e + 000 0 0.00e + 000 2 6.45e + 007 108548.1 5.23 IPI:IPI00291136.3
0 0.00e + 000 0 0.00e + 000 3 5.50e + 007 52247.4 4.90 IPI:IPI00008692.1
0 0.00e + 000 0 0.00e + 000 2 9.76e + 006 30297.3 8.99 IPI:IPI00247243.2
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2 24.57 Keratin, type I cytoskeletal 10 Structural molecule Cellular organization Cytoplasm
activity and biogenesis




2 23.17 Splice Isoform: 2 of Reelin Serine-type peptidase Protein metabolism Extracellular
activity
2 22.19 Breast cancer type 2 Transcription regulator Of nucleobase, Nucleus
susceptibility activity nucleoside, 
protein nucleotide and 
nucleic acid
2 20.75 hypothetical protein DNA binding Signal transduction Nucleus
FLJ10839
1 22.50 Vesicular integral-membrane Transporter activity Immune response Extracellular
protein
1 22.37 Protein tyrosine phosphatase, Enzymatic activity:tyrosine Signal transduction; Endoplasmic 
receptor type, phosphatase Cell communication reticulum
N polypeptide 2
1 21 .78 Cell growth regulator with EF Calcium ion binding Cell cycle arrest Unknown
hand domain 1
1 21.35 Hypothetical protein Unclassified Unclassified Unclassified
FLJ20539
1 21.33 Ephrin type-A receptor 4 Receptor activity Signal transduction Plasma 
membrane
1 20.42 Phosphatidylcholine-sterol Acyltransferase activity Metabolism; Energy Extracellular
pathways
1 20.05 Ribonuclease T2 Enzymatic activity: Of nucleobase, Extracellular
Ribonuclease activity nucleoside, 
nucleotide and 
nucleic acid
1 19.90 Cochlin Extracellular matrix protein Extracellular
1 19.88 Ciliary neurotrophic factor Receptor activity Signal transduction; Plasma 
receptor alpha Cell communication membrane
1 19.83 Frizzled-related protein Transmembrane receptor Signal transduction; Plasma 
activity Cell communication membrane, 
extracellular
1 19.81 Vacuolar ATP synthase Transport activity Transport Plasma 
subunit S1 membrane
1 19.81 Guanine deaminase Catalytic activity neurogenesis, Intracellular
metabolism
1 19.74 Ig superfamily protein Neural cell adhesion Signal transduction Extracellular
molecule
1 19.73 Alpha enolase, lung specific Hydrolase activity Metabolism; Energy Unknown
pathways
1 19.42 Ferritin light chain (Ferritin Transport activity Transport Cytoplasm
L subunit)
1 19.41 72 kDa type IV collagenase Enzymatic activity: Protein metabolism Extracellular
precursor Metallopeptidase
1 19.40 Triosephosphate isomerase Isomerase activity Metabolism; Energy Cytoplasm
pathways
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0 0.00e + 000 0 0.00e + 000 2 2.72e + 007 17196.3 9.22 IPI:IPI00004114.1
0 0.00e + 000 0 0.00e + 000 2 3.94e + 007 59518.9 5.13 IPI:IPI00009865.1
1 2.10e + 007 0 0.00e + 000 2 2.25e + 007 19891.2 6.40 IPI:IPI00298547.1
0 0.00e + 000 0 0.00e + 000 2 7.60e + 007 388217.7 5.54 IPI:IPI00241562.1
1 1.19e + 008 0 0.00e + 000 1 7.11e + 007 384360.4 6.03 IPI:IPI00293471.2
0 0.00e + 000 1 4.36e + 006 1 4.85e + 007 132706.6 8.99 IPI:IPI00217357.1
0 0.00e + 000 0 0.00e + 000 1 2.33e + 007 40228.9 6.06 IPI:IPI00009950.1
0 0.00e + 000 1 4.75e + 006 0 0.00e + 000 114795.6 5.59 IPI:IPI00024289.4
0 0.00e + 000 2 4.61e + 006 0 0.00e + 000 31976.7 4.39 IPI:IPI00008584.1
0 0.00e + 000 0 0.00e + 000 2 8.17e + 007 83181.7 5.28 IPI:IPI00301865.1
0 0.00e + 000 0 0.00e + 000 6 9.45e + 007 109860.6 6.32 IPI:IPI00008318.1
0 0.00e + 000 0 0.00e + 000 1 6.48e + 007 49578.2 5.72 IPI:IPI00022331.1
0 0.00e + 000 1 1.74e + 006 1 5.50e + 006 29708.2 6.2 IPI:IPI00299103.2
0 0.00e + 000 0 0.00e + 000 2 2.41e + 007 59483.3 8.24 IPI:IPI00012386.1
1 3.28e + 006 0 0.00e + 000 0 0.00e + 000 40633.4 6.27 IPI:IPI00003102.1
0 0.00e + 000 0 0.00e + 000 1 3.43e + 007 36254.2 8.63 IPI:IPI00294650.3
0 0.00e + 000 0 0.00e + 000 1 1.63e + 007 52154.2 5.28 IPI:IPI00020430.2
0 0.00e + 000 0 0.00e + 000 2 2.19e + 007 51003.3 5.44 IPI:IPI00032461.1
0 0.00e + 000 0 0.00e + 000 3 2.37e + 007 43987.3 5.92 IPI:IPI00027038.1
0 0.00e + 000 0 0.00e + 000 1 2.71e + 007 49477.6 5.78 IPI:IPI00013769.1
0 0.00e + 000 0 0.00e + 000 2 9.80e + 006 25826.4 5.29 IPI:IPI00074333.1
0 0.00e + 000 0 0.00e + 000 2 1.22e + 008 73882.7 5.26 IPI:IPI00027780.1
0 0.00e + 000 0 0.00e + 000 1 2.23e + 007 26538.4 6.51 IPI:IPI00328807.3
0 0.00e + 000 0 0.00e + 000 3 7.97e + 006 27745.3 4.73 IPI:IPI00021263.1
0 0.00e + 000 0 0.00e + 000 1 2.52e + 007 138884.1 7.98 IPI:IPI00297646.1
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1 19.39 14-3-3 protein zeta/delta Receptor signaling complex Signal transduction; Cytoplasm
(Protein kinase C scaffold activity Cell communication
inhibitor protein
1 19.17 Collagen alpha 1(I) chain Extracellular matrix protein Cellular organization Extracellular
and biogenesis
1 19.14 Parvalbumin alpha Calcium binding protein Signal transduction; Cytoplasm
Cell communication
1 19.05 HGFL protein Growth factor activity Signal transduction; Extracellular
Cell communication
1 18.92 Keratin, type II Structural constituent Cellular organization Cytoplasm
of cytoskeleton and biogenesis
1 18.64 Hypothetical protein Unknown Unknown Unknown
FLJ13813
1 18.34 Malate dehydrogenase Catalytic activity Metabolism; Energy Cytoplasm
pathways
1 18.33 Hypothetical protein Cell adhesion Signal transduction Plasma 
membrane
1 18.05 14-3-3 protein beta/alpha Receptor signaling complex Signal transduction; Cytoplasm
scaffold activity Cell communication
1 18.03 Nidogen Extracellular matrix protein Cellular organization Extracellular
and biogenesis
1 17.97 Nucleobindin 1 Calcium ion binding Signal transduction; Golgi apparatus
Cell communication
1 17.61 Plexin domain containing Receptor activity Signal transduction; Extracellular
2 precursor Cell communication
1 17.34 Neuroserpin Protease Inhibitor activity Protein metabolism Extracellular
1 17.03 Lymphocyte antigen Ly-6H Unknown Immune response / Plasma 
neurogenesis membrane
1 16.89 Major prion protein precursor Unknown Metabolism Plasma 
membrane
1 16.61 Contactin associated Cell adhesion Signal transduction Plasma 
protein-like 4 membrane
1 16.52 Apolipoprotein L1 Transporter activity Transport Extracellular
1 16.31 MIC2L1 isoform E3’-E4’-E3-E4 Unknown Unknown Unknown
1 16.31 similar to cerebellin Unknown Unknown Unknown
1 16.26 Thrombospondin 4 precursor Extracellular matrix protein Cellular organization Extracellular
and biogenesis
1 16.05 Collagen alpha 1(XV) Extracellular matrix protein Cellular organization Extracellular
and biogenesis
1 15.94 Extracellular matrix protein 2 Extracellular matrix protein Cellular organization Extracellular
and biogenesis
1 15.72 Hypothetical protein FLJ90018 Calcium binding protein Unknown
1 15.68 Cystatin B Protease Inhibitor activity Protein metabolism Nucleus
1 15.61 Neurexin 3-alpha precursor Receptor activity Cell adhesion Plasma 
membrane
1 15.58 Ly-6/neurotoxin-like protein 1 Unknown Unknown Unknown
1 15.54 Plasma serine protease inhibitor Protease Inhibitor activity Unknown Extracellular
1 15.51 Hypothetical protein KIAA0315 Receptor activity development Plasma 
membrane
1 15.44 Cell surface glycoprotein Cell adhesion molecule Signal transduction; Plasma 
MUC18 activity Cell communication membrane
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0 0.00e + 000 2 2.43e + 006 0 0.00e + 000 12058.8 4.22 IPI:IPI00219703.1
0 0.00e + 000 2 3.15e + 006 0 0.00e + 000 28248.2 4.77 IPI:IPI00298388.1
0 0.00e + 000 0 0.00e + 000 1 1.06e + 008 56683.2 6.40 IPI:IPI00300053.3
0 0.00e + 000 0 0.00e + 000 1 2.89e + 007 25953.6 6.19 IPI:IPI00030385.1
0 0.00e + 000 0 0.00e + 000 1 1.73e + 007 36426.3 6.89 IPI:IPI00291005.2
0 0.00e + 000 0 0.00e + 000 9 8.01e + 006 24712.7 6.88 IPI:IPI00061246.1
0 0.00e + 000 0 0.00e + 000 1 2.11e + 006 28082.5 4.76 IPI:IPI00216318.1
0 0.00e + 000 0 0.00e + 000 1 5.36e + 006 136489.9 5.09 IPI:IPI00026944.1
0 0.00e + 000 13 3.72e + 006 0 0.00e + 000 53821.6 5.06 IPI:IPI00295542.1
0 0.00e + 000 5 3.91e + 006 0 0.00e + 000 59583.5 5.99 IPI:IPI00044369.1
0 0.00e + 000 0 0.00e + 000 2 4.24e + 007 46427.2 4.84 IPI:IPI00016150.1
0 0.00e + 000 0 0.00e + 000 6 1.57e + 007 14669.1 6.43 IPI:IPI00014964.1
0 0.00e + 000 0 0.00e + 000 2 1.03e + 007 27661.3 9.39 IPI:IPI00022284.1
0 0.00e + 000 0 0.00e + 000 1 2.87e + 007 145660.9 6.22 IPI:IPI00216250.3
0 0.00e + 000 0 0.00e + 000 1 4.17e + 007 44026.6 5.71 IPI:IPI00177869.4
0 0.00e + 000 2 4.06e + 006 0 0.00e + 000 27986.0 4.92 IPI:IPI00152491.1
0 0.00e + 000 0 0.00e + 000 1 1.46e + 007 21520.7 6.72 IPI:IPI00402157.1
0 0.00e + 000 0 0.00e + 000 2 3.91e + 006 105802.9 4.44 IPI:IPI00328550.2
0 0.00e + 000 0 0.00e + 000 3 1.06e + 007 142569.9 5.3 IPI:IPI00295414.3
0 0.00e + 000 0 0.00e + 000 1 6.71e + 007 79789.8 5.30 IPI:IPI00015315.1
0 0.00e + 000 0 0.00e + 000 1 1.43e + 008 68667.7 4.49 IPI:IPI00384073.1
0 0.00e + 000 0 0.00e + 000 1 7.41e + 007 11139.6 6.98 IPI:IPI00021828.1
0 0.00e + 000 0 0.00e + 000 1 1.32e + 008 169924.4 5.76 IPI:IPI00006300.2
0 0.00e + 000 0 0.00e + 000 13 5.39e + 007 12641.1 8.09 IPI:IPI00289058.3
0 0.00e + 000 0 0.00e + 000 3 1.22e + 007 45702.0 9.35 IPI:IPI00007221.1
0 0.00e + 000 0 0.00e + 000 1 1.07e + 008 205412.7 5.88 IPI:IPI00004462.1
0 0.00e + 000 2 4.79e + 006 0 0.00e + 000 71794.0 5.52 IPI:IPI00016334.1
0 0.00e + 000 4 4.57e + 006 0 0.00e + 000 61133.3 5.39 IPI:IPI00218413.1
0 0.00e + 000 0 0.00e + 000 6 2.32e + 007 40526.9 9.67 IPI:IPI00013909.1
0 0.00e + 000 0 0.00e + 000 1 7.91e + 006 20927.3 6.59 IPI:IPI00164876.1
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1 15.35 Biotinidase Hydrolase activity Metabolism; Energy Extracellular
pathways
1 14.92 Apoptosis-inducing factor Receptor activity Signal transduction; Plasma 
(AIF)-like mitochondrion- Cell communication membrane
associated inducer of 
death
1 14.91 BA145L22.1.2 Cell adhesion molecule Signal transduction; Plasma 
(Myelin/oligodendrocyte activity Cell communication membrane
glycoprotein (MOG)
1 14.72 Opioid binding protein opioid receptor activity Signal transduction; Plasma 
Cell communication membrane
1 14.70 Phosphoglycerate mutase 2 Catalytic activity Metabolism; Energy Cytoplasm
pathways
1 14.52 Phosphoglycerate kinase 1 Catalytic activity Metabolism; Energy Cytoplasm
pathways
1 14.43 hypothetical protein FLJ10006 Unknown Unknown Unknown
1 14.08 Keratin, type I Structural constituent Cellular organization Cytoplasm
of cytoskeleton and biogenesis
1 13.84 hypothetical protein Unknown Unknown Unknown
MGC22776
1 13.82 Splice form of interleukin-6 Receptor activity: Immune response Plasma 
receptor beta chain transmembrane membrane
1 13.68 Proenkephalin A neuropeptide hormone Signal transduction Cytoplasm
activity
1 13.66 GAS2-related protein Unknown Unknown Unknown
1 13.65 similar to Ba1-651 Unknown Unknown Unknown
1 13.54 endoglycan Binding:glycosaminoglycan Plasma 
binding membrane
1 13.46 hypothetical protein XP_376158 Unknown Unknown Unknown
1 13.44 BA416N2.2 signal transduction Signal transduction Plasma 
membrane
1 13.21 Transgelin Structural constituent Cellular organization Cytoplasm
of cytoskeleton and biogenesis
1 13.04 Alpha-2-antiplasmin Protease Inhibitor activity Unknown Extracellular
1 13.03 HGF activator like protein Binding protein Cell adhesion Extracellular
(Hyaluronan binding 
protein 2)
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weight than the one predicted for the respec-
tive full-length protein.
Conclusions
As was anticipated at the outset of these
studies, we have confirmed that extensive
prefractionation of complex protein mixtures
leads to an increased coverage of the sample’s
protein constituents. This is exemplified by
using AEC or SDS-PAGE to separate CSF pro-
tein mixtures that had been previously
immunodepleted of the six most abundant
Immunodepletion Immunodepletion and AEC Immunodepletion and SDS-PAGE
Number Mean Number Mean Number Mean Accession 
of spectra intensity of spectra intensity of spectra intensity Mw pl number
0 0.00e + 000 0 0.00e + 000 3 1.43e + 008 38007.8 5.89 IPI:IPI00001662.1
0 0.00e + 000 0 0.00e + 000 1 1.11e + 007 28850.3 9 IPI:IPI00218570.1
0 0.00e + 000 0 0.00e + 000 1 2.98e + 007 44615.0 9.22 IPI:IPI00169383.1
0 0.00e + 000 0 0.00e + 000 22 1.20e + 008 91955.0 4.43 IPI:IPI00296432.1
0 0.00e + 000 0 0.00e + 000 2 5.30e + 006 62064.6 5.14 IPI:IPI00019359.2
1 4.97e + 007 3 6.83e + 006 0 0.00e + 000 25431.2 7.82 IPI:IPI00163563.1
0 0.00e + 000 0 0.00e + 000 2 3.94e + 007 37484.7 5.46 IPI:IPI00218963.1
0 0.00e + 000 1 3.39e + 006 0 0.00e + 000 30787.2 5.44 IPI:IPI00000828.1
10 1.34e + 008 16 6.74e + 006 0 0.00e + 000 96520.4 10.21 IPI:IPI00169377.1
0 0.00e + 000 0 0.00e + 000 2 1.99e + 008 65929.3 5.27 IPI:IPI00402024.1
0 0.00e + 000 0 0.00e + 000 1 1.03e + 008 65076.1 4.12 IPI:IPI00024585.1
2 1.66e + 008 2 2.42e + 007 0 0.00e + 000 722928.1 6.04 IPI:IPI00400963.1
0 0.00e + 000 0 0.00e + 000 7 2.17e + 007 115717.9 8.75 IPI:IPI00400923.1
0 0.00e + 000 0 0.00e + 000 2 2.28e + 007 22475.9 8.88 IPI:IPI00216138.1
0 0.00e + 000 0 0.00e + 000 1 3.02e + 007 54566.1 5.87 IPI:IPI00029863.1
0 0.00e + 000 0 0.00e + 000 1 7.55e + 007 63832.5 6.1 IPI:IPI00041065.2
The proteins were identified by subjecting MS/MS data of the tryptic peptides to Spectrum Mill (9) analysis
using default extraction and search parameters. The Spectrum Mill software ranks the proteins according to the
number of unique peptides that were identified for all three runs. Proteins that are present in two comprehensive
human serum databases (10,11) are indicated with a bold font in the “Protein name” column.
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proteins. The subsequent shotgun mass spec-
trometry and protein identification analyses
benefit from both the removal of abundant
proteins as well as prefractionation of the CSF
sample on the protein level. This is a result of
the generation of a smaller dynamic range of
the remaining protein mixture. In addition,
because of the smaller amount of total protein
that results from the combination of immun-
odepletion and prefractionation, a greater
equivalent of the CSF sample can be used dur-
ing the shotgun mass spectrometry analysis
Fig. 4. Protein categories that were identified in cerebrospinal fluid from a patient with normal pressure
hydrocephalus after immunodepletion and protein prefractionation followed by shotgun mass spectrometry anal-
ysis. Proteins are grouped according to the Gene Ontology Consortium (http://www.geneontology.org) classifi-
cation by molecular function (A), involvement in biological processes (B), and cellular compartment location (C).
Fig. 5. Predicted isoelectric point (pI) and molecular weight (Mw) of proteins that were identified in the
cerebrospinal fluid proteome.The information is based on the full-length sequences of the proteins as they are
listed in the human IPI protein database.
Clinical Proteomics _______________________________________________________________ Volume 1, 2004
362 ___________________________________________________________________________ Maccarrone et al.
Volume 1, 2004 _______________________________________________________________ Clinical Proteomics
Human CSF Proteome ______________________________________________________________________ 363
without the risk of overloading the reversed-
phase nano column that is used on-line with
the mass spectrometer. Our previous attempts
to use crude CSF (neither immunodepleted
nor prefractionated) in a shotgun mass spec-
trometry analysis resulted in only 38 proteins
that were identified as a result of the over-
whelming presence of HSA, Ig, and other
abundant protein-derived peptides (data not
shown).
Approximately 47% of the CSF proteins
that we identified were also found during in-
depth proteomic analyses of human serum
(10,11). This partial overlap can be attributed
to the following observations. On one hand,
as discussed above, there is an inherently low
overlap between shotgun analyses, especially
when performed in different laboratories
using different fractionation approaches and
different equipment. Second, there is variabil-
ity between the individuals whose body
fluids were analyzed. Third, certain proteins
are removed in the process of generating
serum from blood and hence will not show
up in the serum protein list. Finally, brain-
derived proteins are present in larger
amounts in CSF than in serum because of the
proximity of CSF and the brain and the rather
low exchange between the two body fluids.
The latter reason makes CSF the most rele-
vant source for a proteomics study that is
aimed at the identification of markers for
brain disorders. The CSF flow rate has been
recognized as the key modulator of blood-
derived and brain-derived proteins in this
body fluid. A close approximation of the pro-
tein portion that is derived from blood can be
gained by measuring the CSF/blood albumin
ratio (12). However, at the same time, it has
been shown that blood-derived proteins in
CSF follow a hyperbolic function, which
depends primarily on the molecular weight of
the proteins (12).
Other reports that describe attempts to
analyze the CSF proteome have been published.
Most of these studies have used 2D-PAGE for
sample preparation followed by mass spectro-
metric identification of the stained protein
spots. The most detailed analysis of CSF pro-
tein constituents up to now has been per-
formed by Sickmann et al. (13). The analysis
of over 480 protein spots from a 2D-PAGE
fractionation of undepleted CSF resulted in
the identification of 24 proteins from 65 spots,
of which 15 were also found in our analyses.
As expected, many proteins were identified
multiple times because of the great number of
protein isoforms found in CSF. In another
report, Davidsson et al. used preparative
liquid isoelectric focusing in combination with
one-dimensional SDS gel electrophoresis for
the identification of 32 CSF proteins, of which
we identified 24 proteins in our analyses (14).
This procedure was able to identify a number
of low abundant proteins in undepleted CSF
samples because of the concentration in a few
fractions of the abundant HSA and Ig proteins
during the preparative isoelectric focusing
step.
In our future studies, we will continue our
CSF proteome mining efforts by trying to iden-
tify protein constituents of ever lower abun-
dance. This will require not only the use of
further fractionation steps, but, at the same
time, the use of increased amounts of CSF
material. Furthermore, we have begun to
extend our strategies by establishing a pro-
teomic platform that will allow us to compare
the quantities of many proteins between differ-
ent CSF samples. The quantitative approach
will enable us to compare CSFs from different
patient groups and result in the identification
of patterns of proteins that are up- or down-
regulated, leading to important markers of
brain disease.
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